Assessing heart function in patients with right heart failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to improve the understanding and diagnosis of right ventricular (RV) myocyte dysfunction in patients suffering from heart failure with reduced ejection fraction and pulmonary hypertension (HFrEF-PH). The investigators will identify clinical indicators of RV myocyte contractile failure and explore underlying mechanisms. By measuring RV contractile reserve during exercise, the study seeks to provide insights that could lead to better prognostic and therapeutic strategies for RV failure. The ultimate goal is to enhance the identification and treatment of RV dysfunction in earlier stages of heart failure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients aged between 18 and 90 years of age
* Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%)
* Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure

Exclusion Criteria:

* Unable to interrupt VKA anticoagulation
* Point of care International Normalized Ratio (INR) \> 1.5
* Pregnant patients
* Acute hospitalization or decompensation within 2 weeks prior to study date
* Participation in a study involving an investigational drug within 4 weeks prior to study date
* Inability to lie flat in the supine position
* Symptomatic hemodynamic instability at rest or during the procedure

Where it's running

• Johns Hopkins Hospital
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Steven Hsu, MD — Johns Hopkins School of Medicine
• Study coordinator: Steven Hsu, MD
• Email: steven.hsu@jhmi.edu
• Phone: 410-502-0955

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pulmonary Artery Denervation for a specific type of heart and lung pressure problem

  This study tests whether the Enhancor System can safely and effectively help patients with combined pre- and post-capillary pulmonary hypertension due to left heart disease when added to standard therapy.

  Recruiting at 18 sites Pulnovo Medical, Inc. · Tucson, Arizona and 18 other locations · NCT07214376

• Levosimendan to see if it helps the heart after PEA in CTEPH

  This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.

  Recruiting Meshalkin Research Institute of Pathology of Circulation · Novosibirsk · NCT07914933

• Early treatment with inhaled treprostinil for exercise-induced pulmonary hypertension in ILD or CTD

  This study tests whether inhaled treprostinil added to standard care can improve exercise-related lung blood flow and function in adults with ILD or CTD who develop pulmonary hypertension during exercise.

  Recruiting at 2 sites Early Phase 1 Valley Health System · Paramus, New Jersey and 1 other locations · NCT07837830

• Brazilian Portuguese version of EmPHasis-10 for pulmonary hypertension

  This study tests a Brazilian Portuguese version of the EmPHasis-10 questionnaire to see if it reliably measures quality of life in adults with pulmonary hypertension in Porto Alegre, Brazil.

  Recruiting Hospital de Clinicas de Porto Alegre · Porto Alegre · NCT07822997

• Yoga-based cardiac rehabilitation for heart failure with reduced ejection fraction

  This trial tests whether a yoga-based rehabilitation program can help people with heart failure and reduced ejection fraction compared with an educational program.

  Recruiting at 12 sites Centre for Chronic Disease Control, India · Dharwad, Karnataka and 15 other locations · NCT07817589

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.